A multicenter, double-blind, placebo-controlled, randomized study drug Runihol® in patients with nonalcoholic fatty liver disease and metabolic syndrome

Trial Profile

A multicenter, double-blind, placebo-controlled, randomized study drug Runihol® in patients with nonalcoholic fatty liver disease and metabolic syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Inosine (Primary)
  • Indications Liver disorders; Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Sponsors POLYSAN
  • Most Recent Events

    • 16 Jan 2018 Planned End Date changed from 1 Nov 2017 to 1 Nov 2020.
    • 16 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2020.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top